PRO MEDICUS LIMITED (PME)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PME

PME - PRO MEDICUS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.02
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS | ALL-TECH

Pro Medicus is an imaging IT company providing a range of radiology software and services, medical accounting and clinical reporting to the health care sector. Founded in 1983, the company listed on the ASX in 2000.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$317.00

14 Jul
2025

-0.340

OPEN

$319.34

-0.11%

HIGH

$321.99

99,457

LOW

$314.91

TARGET
$274.567 -13.4% downside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
PME: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 79.3 109.2 xxx
DPS (cps) xxx 40.0 53.6 xxx
EPS Growth xxx 36.5% 37.8% xxx
DPS Growth xxx 33.3% 33.9% xxx
PE Ratio xxx N/A 297.3 xxx
Dividend Yield xxx N/A 0.2% xxx
Div Pay Ratio(%) xxx 50.5% 49.0% xxx

Dividend yield today if purchased 3 years ago: 0.88%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.12

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 04/09 - ex-div 22c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx79.3
DPS All xxxxxxxxxxxxxxx40.0
Sales/Revenue xxxxxxxxxxxxxxx161.5 M
Book Value Per Share xxxxxxxxxxxxxxx179.8
Net Operating Cash Flow xxxxxxxxxxxxxxx86.8 M
Net Profit Margin xxxxxxxxxxxxxxx51.27 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx50.72 %
Return on Invested Capital xxxxxxxxxxxxxxx50.30 %
Return on Assets xxxxxxxxxxxxxxx36.03 %
Return on Equity xxxxxxxxxxxxxxx50.72 %
Return on Total Capital xxxxxxxxxxxxxxx67.94 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx49.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx2 M
Total Debt xxxxxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx155 M
Price To Book Value xxxxxxxxxxxxxxx79.69

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx6.7 M
Capex % of Sales xxxxxxxxxxxxxxx4.14 %
Cost of Goods Sold xxxxxxxxxxxxxxx39 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx10 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx7 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

-0.1

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

3

xxxxxxxxx xx xxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

4

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

04/07/2025

3

Hold

$305.00

-3.79%

Pro Medicus announced two contracts worth at least $190m. One with UCHealth, which is a ten-year deal for $170m for the Colorado-based operator of 13 hospitals and one care facility.

Ord Minnett notes this includes the first licensing of the company's cardiology suite of its Visage 7 enterprise imaging platform.

The second contract is a renewal for at least $20m with Franciscan Missionaries of Our Lady Health System.

The broker stresses the tender process for UCHealth was very competitive and emphasises the "strength" of the Visage 7 product, as it is notably more expensive than other peers' systems.

Target moves to $305 from $275 with no change to Hold rating.

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

5

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Moelis

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Wilsons

07/07/2025

3

Market Weight

$325.00

2.52%

Wilsons maintains a Market Weight rating on Pro Medicus and raises its price target to $325 from $297 following the $170m, 10-year UCHealth contract win. The higher target essentially tracks with the broker's long-term free cash flow upgrades.

UCHealth is a large, not-for-profit health network, whose complexity and scope necessitates large scale investment in IT infrastructure to support productivity and security, explains the broker.

The deal includes cardiology and strengthens the company's foothold in large, expanding US not-for-profit hospital networks, believe the analysts.

Wilsons upgrades its FY27 revenue forecast by 5% and lifts FY26 and FY27 profit forecasts by 8% and 9%, respectively, citing margin expansion from recent large contract wins.

The broker notes UCHealth now becomes a high-profile reference site for Visage 7 in the US Midwest.

While the analysts view the Pro Medicus valuation as high, it is seen as justified by long-term, GDP-plus free cash flow growth potential and the stock's undeniable corporate appeal.

FORECAST
Wilsons forecasts a full year FY25 dividend of 54.50 cents and EPS of 109.30 cents.
Wilsons forecasts a full year FY26 dividend of 73.10 cents and EPS of 147.90 cents.
Access Extra Coverage Research History >

PME STOCK CHART

FNArena News on PME

1
Rudi’s View: Gold stocks & Miners, DigiCo, Pinnacle & More

Jul 10 2025 - Rudi's View
2
Strength To ‘AI’ Strength For Pro Medicus

Jul 10 2025 - Australia
3
Australian Broker Call *Extra* Edition – Jul 09, 2025

Jul 09 2025 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Jul 07, 2025

Jul 07 2025 - Daily Market Reports
5
Investing In AI & Growth; A Personal Experience

Jul 07 2025 - International

Latest Medical Equipment & Devices News

1
Strength To ‘AI’ Strength For Pro Medicus

Jul 10 2025 - Australia
2
Cochlear Downgrades Ahead Of New Launches

Jun 19 2025 - Australia
3
Fisher & Paykel Healthcare’s Tariffs Annoyance

Jun 04 2025 - Australia
4
ResMed’s Margin Expansion & Tariff Exemption

Apr 28 2025 - Australia
5
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
6
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus
7
ResMed Shakes Off GLP-1 Scare

Feb 04 2025 - Australia
8
ResMed: Another Positive Quarterly Surprise?

Jan 30 2025 - Australia
9
The Trend Remains Pro Medicus’ Friend

Jan 16 2025 - Technicals
10
Diagnostic Imaging Radiates Opportunity

Dec 18 2024 - Small Caps